Acquisitive Lilly offers $2.88bn for Merida Bio
Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.
ESC26: Heart attack reclassification rights gender imbalance
New definitions of myocardial infarction released at ESC 2026 recognise that there are different causes - and could lead to better treatment of women.
ESC26: Isomab safety evidence on blood vessel growth for CAD
Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Roivant wins FDA approval for first targeted dermatomyositis...
Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.
Anthropic AI tool conducts physical scientific experiments
Anthropic has opened a research preview of its Model Hardware Standard (MHS), the company's first tool designed to operate in the physical world.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
AI, Forecasting, Insights and Analytics for Smarter Decision...
Learn from case studies, expert-led panels, roundtable discussions, and interactive workshops on Gen AI-powered forecasting
30th Portfolio Decision-Making & Prioritisation for Pharma
Pharmaceutical portfolio decision-making is facing structural pressure.
R&D Governance, Controlling and Innovation for Pharma
The Marcus Evans R&D Governance, Controlling, and Innovation for Pharma conference will take place at the Crowne Plaza - Frankfurt Congress Hotel
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.